NEW!

In the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME) trial, empagliflozin demonstrated a reduction in cardiovascular events in patients with type 2 diabetes mellitus (T2DM) and pre-existing cardiovascular disease. This online course covers the evidence base on the use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, in the management of T2DM patients with heart failure and chronic kidney disease.

Professor Steven Kahn discusses the data from the EMPA-REG OUTCOME study. Professor Javed Butler, an investigator of the EMPEROR-Reduced trial presents new data on empagliflozin in reducing the risk of cardiovascular death and hospitalisation for heart failure. Professor Katherine Tuttle reviews the therapeutic approaches and recommendations for patients with diabetic kidney disease (DKD), focusing on SGLT2 inhibitors.

CPD Reviewers:

Professor Katherine Tuttle, MD, FASN, FACP, FNKF
Professor of Medicine, Division of Nephrology, Department of Medicine
University of Washington School of Medicine

Professor Steven Kahn, MB, ChB
Professor of Medicine
Leonard L. Wright and Marjorie C. Wright Chair
Division of Metabolism, Endocrinology and Nutrition
University of Washington School of Medicine

Professor Javed Butler, MD, MPH, MBA
Patrick A. Lehan Chair in Cardiovascular Research
Professor and Chairman, Department of Medicine
Professor of Physiology, University of Mississippi Medical Center

NOTE :
Please watch the video before attempting the assessment questions.

Terms & Conditions: 
■ Participants must obtain a minimum score of 8/10 (80%) to be awarded 1 point. 
■ MIMS Education and MIMS Medica shall not be responsible or liable for the outcome of your CPD points

To play this video, you are required to have a media player such as Windows Media Player (PC), QuickTime (MAC) or another third party media player.

Sponsored by: